TopFunds

Zoetis

NYSE: ZTS

Stock price

80.98 USD

(+0%) TODAY

PharmaceuticalsDrug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
0.7
1.7
1.8
2.9
3.1
3.4
4.3
4.5
5.1
5.5
6
24.4%
02Free cash flow per share
0.9
1
2.3
3
2.8
3.5
3.6
2.8
3.5
5.1
5.1
19.4%
03Dividends per share
0.3
0.4
0.4
0.5
0.7
0.8
1
1.3
1.5
1.7
2
19.7%
04Dividends payout, %
49.6%
22.9%
23.8%
17%
20.9%
23.2%
23.3%
28.9%
29.5%
31.6%
33.3%
(3.9)%
PROFIT AND LOSS STATEMENT
05Revenue
$ 4,765
$ 4,888
$ 5,307
$ 5,825
$ 6,260
$ 6,675
$ 7,776
$ 8,080
$ 8,544
$ 9,256
$ 9,467
7.1%
06% Change
-
2.6%
8.6%
9.8%
7.5%
6.6%
16.5%
3.9%
5.7%
8.3%
2.3%
7.1%
07Cost of revenue
(1,798)
(1,745)
(1,864)
(2,028)
(2,147)
(2,217)
(2,464)
(2,604)
(2,710)
(2,860)
(2,794)
4.5%
08Gross profit
2,967
3,143
3,443
3,797
4,113
4,458
5,312
5,476
5,834
6,396
6,673
8.4%
09% Margin
62.3%
64.3%
64.9%
65.2%
65.7%
66.8%
68.3%
67.8%
68.3%
69.1%
70.5%
66.6% A
10Operating expenses
(1,885)
(1,739)
(1,716)
(1,916)
(2,095)
(2,189)
(2,509)
(2,548)
(2,765)
(3,004)
(3,076)
5%
11% of Revenue
(39.6)%
(35.6)%
(32.3)%
(32.9)%
(33.5)%
(32.8)%
(32.3)%
(31.5)%
(32.4)%
(32.5)%
(32.5)%
(33.4)% A
12Operating Income
1,082
1,404
1,727
1,881
2,018
2,269
2,803
2,928
3,069
3,392
3,597
12.8%
13Income tax expense
(206)
(409)
(663)
(266)
(301)
(360)
(454)
(545)
(596)
(637)
(687)
12.8%
14Net Income
339
821
864
1,428
1,500
1,638
2,037
2,114
2,344
2,486
2,673
22.9%
15% Margin
7.1%
16.8%
16.3%
24.5%
24%
24.5%
26.2%
26.2%
27.4%
26.9%
28.2%
22.6% A
16Shares Outstanding
502,019
498,225
493,161
486,898
481,787
478,569
476,717
470,385
462,269
454,848
443,835
(1.2)%
17EPS Basic
0.7
1.7
1.8
3
3.1
3.4
4.3
4.5
5.1
5.5
6
24.4%
18EPS Diluted
0.7
1.7
1.8
2.9
3.1
3.4
4.3
4.5
5.1
5.5
6
24.4%
19EBITDA
868
1,634
1,942
2,210
2,455
2,686
3,172
3,358
3,685
3,872
4,069
16.7%
% Margin
18.2%
33.4%
36.6%
37.9%
39.2%
40.2%
40.8%
41.6%
43.1%
41.8%
43%
37.8% A
20Net Interest Income (expense)
(124)
(166)
(175)
(181)
(205)
(237)
(230)
(187)
(153)
(136)
(150)
1.9%
21Net Debt / EBITDA
4.3
2.3
1.7
2.2
1.9
1.4
1
1.3
1.3
1.2
1.8
1.9 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
1,154
727
1,564
1,597
1,932
3,602
3,482
3,577
2,039
1,985
2,312
7.2%
23Short-term investments
-
-
-
99
-
-
-
-
-
-
-
-
24Accounts receivable
937
913
998
1,036
1,086
1,013
1,133
1,215
1,304
1,316
1,590
5.4%
25Other current assets
272
248
228
276
320
368
392
369
436
379
436
4.8%
26Inventory
1,467
1,502
1,427
1,391
1,410
1,628
1,923
2,345
2,564
2,306
2,430
5.2%
27Total Current Assets
3,830
3,390
4,217
4,399
4,748
6,611
6,930
7,506
6,343
5,986
6,768
5.9%
Non-Current Assets
28Net property, plant & equipment
1,307
1,381
1,435
1,658
2,129
2,394
2,603
2,973
3,434
3,610
3,969
11.8%
29Long-term investments
-
-
-
-
-
-
-
-
-
30
-
-
30Other non-current assets
2,776
2,878
2,934
4,720
4,668
4,604
4,367
4,446
4,509
4,611
4,730
5.5%
31Total Non-Current Assets
4,083
4,259
4,369
6,378
6,797
6,998
6,970
7,419
7,943
8,251
8,699
7.9%
Total Assets
7,913
7,649
8,586
10,777
11,545
13,609
13,900
14,925
14,286
14,237
15,467
6.9%
LIABILITIES
Current Liabilities
32Accounts payable
293
265
261
313
301
457
436
405
411
433
487
5.2%
33Short-term debt
405
-
-
9
500
604
-
1,352
3
1,350
53
(18.4)%
34Other current liabilities
1,083
852
833
901
1,005
1,109
1,361
1,410
1,475
1,629
1,695
4.6%
35Total Current Liabilities
1,781
1,117
1,094
1,223
1,806
2,170
1,797
3,167
1,889
3,412
2,235
2.3%
Non-Current Liabilities
36Long-term debt
4,463
4,468
4,953
6,443
6,111
6,758
6,743
6,738
6,752
5,394
9,440
7.8%
37Other non-current liabilities
578
565
753
926
920
908
816
617
654
661
461
(2.2)%
38Total Non-Current Liabilities
5,041
5,033
5,706
7,369
7,031
7,666
7,559
7,355
7,406
6,055
9,901
7%
39Total Liabilities
6,822
6,150
6,800
8,592
8,837
9,836
9,356
10,522
9,295
9,467
12,136
5.9%
SHAREHOLDERS` EQUITY
40Common stock
5
5
5
5
5
5
5
5
5
5
5
-
41Retained earnings / (deficit)
876
1,477
2,109
3,270
4,427
5,659
7,186
8,668
10,295
11,968
13,744
31.7%
42Accumulated other comprehensive income / (loss)
(622)
(598)
(505)
(629)
(726)
(730)
(764)
(817)
(839)
(940)
(834)
3%
43Noncontrolling interests
23
12
16
-
-
4
1
(2)
(6)
-
-
-
44Total shareholders' equity
1,091
1,499
1,786
2,185
2,708
3,773
4,544
4,403
4,991
4,770
3,331
11.8%
45Total Liabilities and shareholders' Equity
7,913
7,649
8,586
10,777
11,545
13,609
13,900
14,925
14,286
14,237
15,467
6.9%
46Total Debt
4,868
4,468
4,953
6,452
6,611
7,362
6,743
8,090
6,755
6,744
9,493
6.9%
47Net Debt
3,714
3,741
3,389
4,855
4,679
3,760
3,261
4,513
4,716
4,759
7,181
6.8%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
339
821
864
1,428
1,500
1,638
2,037
2,114
2,344
2,486
2,673
22.9%
49Depreciation & amortization
199
240
242
308
412
441
448
465
491
497
487
9.4%
50Share-based compensation expense
43
37
44
53
67
59
58
62
60
74
83
6.8%
51Changes in working capital and other assets
83
(385)
196
1
(184)
(12)
(330)
(729)
(542)
(104)
(339)
-
52Net cash flows from operating activities
664
713
1,346
1,790
1,795
2,126
2,213
1,912
2,353
2,953
2,904
15.9%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(224)
(216)
(224)
(338)
(460)
(453)
(477)
(586)
(732)
(655)
(621)
10.7%
54Purchases of investments / marketable securities
-
-
-
338
460
(27)
(12)
(9)
(4)
(5)
(7)
-
55Proceeds from maturities of marketable securities
-
-
-
28
138
453
44
23
12
62
-
-
56Other investing activities
(891)
2
(46)
(2,287)
(642)
(545)
(13)
(311)
(53)
283
(120)
(18.2)%
57Net cash flows from investing activities
(1,115)
(214)
(270)
(2,259)
(504)
(572)
(458)
(883)
(777)
(315)
(748)
(3.9)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(203)
(300)
(500)
(698)
(626)
(250)
(743)
(1,594)
(1,092)
(1,858)
(3,235)
31.9%
59Dividends paid, net
(168)
(188)
(206)
(243)
(314)
(380)
(474)
(611)
(692)
(786)
(889)
18.1%
60Debt issuance (repayments), net
1,115
(405)
481
1,504
(9)
744
(604)
1,350
(1,349)
(3)
2,268
7.4%
61Other financing activities
11
(10)
(26)
(30)
(2)
9
(41)
(49)
24
(13)
(14)
-
62Net cash flows from financing activities
755
(903)
(251)
533
(951)
123
(1,862)
(904)
(3,109)
(2,660)
(1,870)
-
63Increase (decrease) in cash and cash equivalents
272
(427)
837
38
332
1,670
(119)
96
(1,540)
(54)
325
1.8%
64Cash and equivalents, ending balance
1,154
727
1,564
1,602
1,934
3,604
3,485
3,581
2,041
1,987
2,312
7.2%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
440
497
1,122
1,452
1,335
1,673
1,736
1,326
1,621
2,298
2,283
17.9%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Zoetis (ZTS) financial statements and performance

Explore Zoetis (ZTS) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.